Delivery Order SPE2DB22D3016-SPE2DB25FBKP9
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 20, 2025, for the supply of Ibsrela 50 mg tablets (60-count units) under a firm fixed-price contract valued at $21,030.84, with completion expected by August 21, 2025. This competitively awarded, non-set-aside delivery order represents a routine pharmaceutical procurement supporting federal medical supply needs. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as a...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 5, 2025, for the supply of Ibsrela 50 mg tablets (60-count unit) valued at $1,926.04. This firm fixed-price contract, which reaches completion on August 6, 2025, represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion vehicle running through December 2026. The delivery order carries no set-aside...
- The Defense Logistics Agency awarded a delivery order valued at $5,086.77 to AmerisourceBergen Drug Corp for the supply of Ibsrela 50 mg tablets (60-count units) on August 28, 2025, with an ultimate completion date of August 29, 2025. This competitively awarded, firm fixed-price contract includes no set-aside designation and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare...
- AmerisourceBergen Drug Corp was awarded a delivery order valued at $26,193.92 by the Defense Logistics Agency on August 7, 2025, for the supply of Ibsrela 50 mg tablets in quantities of 60 units. This is a firm fixed-price delivery order with no set-aside designation, indicating the award was made through open competition. The contract will be performed at the company's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of August 8, 2025. This delivery...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $5,691.58 to AmerisourceBergen Drug Corp for the supply of Ibsrela 50 mg tablets (60-count units) under a firm fixed-price contract. The award was made on July 21, 2025, with an ultimate completion date of July 22, 2025, and represents a non-set-aside, competitively awarded procurement. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location in the same...
- The U.S. Department of Defense Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on September 17, 2025, for the supply of Ibsrela 50 mg tablets (60-count units) under a firm fixed-price contract valued at $3,784.00, with completion targeted for September 18, 2025. This is a competitively awarded, non-set-aside delivery order issued by the federal government's medical procurement division. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform...
- The Defense Logistics Agency awarded a delivery order valued at $3,047.31 to AmerisourceBergen Drug Corp for 60 tablets of Ibsrela 50 mg on June 27, 2025. This competitive award, issued without set-aside provisions, is structured as a firm fixed price delivery order with an ultimate completion date of June 30, 2025. The pharmaceutical product will be delivered to the Conshohocken, Pennsylvania location, where AmerisourceBergen Drug Corp maintains its corporate office. This delivery order...
- The Defense Logistics Agency awarded a delivery order valued at $6,909.82 to AmerisourceBergen Drug Corp for Ibsrela 50 mg tablets (60-count units) on September 3, 2025, with completion expected by September 4, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at the contractor's Conshohocken, Pennsylvania location. The award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC)...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 31, 2025, for the supply of Ibsrela 50 mg tablets (60 count) under a firm fixed-price contract valued at $4,847.75. This non-set-aside award is a child contract executed under AmerisourceBergen's larger Indefinite Delivery Contract (SPE2DX) with DLA Troop Support Medical, a $999.99 billion vehicle that runs through December 2026 and supports pharmaceutical procurement for military and veteran...
- The Defense Logistics Agency awarded a $3,431.04 firm fixed-price delivery order to AmerisourceBergen Drug Corp on June 18, 2025, for the supply of Ibsrela 50 mg tablets (60-count units). This non-set-aside contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. Performance will be executed from the contractor's Conshohocken, Pennsylvania location,...
- SPE2DB22D3016Indefinite Delivery Contract
- SPE2DB22D3016-SPE2DB25FBKP9Delivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 23, 2025, for the supply of Ibsrela 50 mg tablets (60-count units) with a ceiling value of $3,425.94. This is a firm fixed-price, competitively awarded delivery order with no set-aside designation and an ultimate completion date of September 24, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform this work at its corporate office location in Pennsylvania. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is valued at $999,999,999.00 and extends through December 2026. This comprehensive global pharmaceutical support vehicle enables the contractor to supply a broad range of pharmaceutical products and medical supplies to support military healthcare programs and the Defense Health Agency worldwide. AmerisourceBergen Drug Corp's consistent performance across multiple delivery orders and its significant prime indefinite delivery contract demonstrate its established capability to meet federal medical supply requirements through open competition.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.4k | 9/23/25 |